Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the rate of positive sentinel lymph nodes
(i.e. the closest draining lymph node(s) to the primary melanoma site) and to test whether
treatment with pembrolizumab before surgery to remove melanoma reduces the rate of positive
sentinel lymph nodes in patients with Stage IIB/C melanoma.
Subjects with stage II melanoma will receive one dose of pembrolizumab 200 mg, then undergo
standard definitive surgery with wide excision and sentinel lymph node (SLN) biopsy
approximately 3 weeks after the initial dose of pembrolizumab. Post-operatively, subjects
will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania